-
-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate](/abs-image/US/2008/08/07/US20080188513A1/abs.jpg.150x150.jpg)
1.发明申请1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate 审中-公开1-（2-甲基丙基）-1H-咪唑并[4,5-C]（1,5]萘啶-4-胺乙磺酸盐和1-（2-甲基丙基）-1H-咪唑并[4,5-C]（1 ，5]萘啶-4-胺甲磺酸盐公开(公告)号：US20080188513A1
公开(公告)日：2008-08-07
申请号：US11813005
申请日：2005-12-28
IPC分类号： A61K31/4375 , C07D471/14 , A61P31/12
CPC分类号： C07D471/14
摘要： This invention provides methanesulfonate and ethanesulfonate salts of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine, pharmaceutical compositions containing the salts, methods of making, and methods of use.
摘要翻译： 本发明提供1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1,5]萘啶-4-胺的甲磺酸盐和乙磺酸盐，含有盐的药物组合物，制备方法和方法 使用。
-
![Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate](/abs-image/US/2009/05/14/US20090124652A1/abs.jpg.150x150.jpg)
2.发明申请Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate 审中-公开1-（2-甲基丙基）-1H-咪唑并[4,5-C] [1,5]萘啶-4-胺乙烷磺酸盐的多晶型物公开(公告)号：US20090124652A1
公开(公告)日：2009-05-14
申请号：US11813007
申请日：2005-12-28
申请人： David Ach , Hughes Martin , Anna Van , Joel R. Jacobson , Junshi Y. Wu , Kyle J. Lindstrom , Tai T. Tran , Myles L. Brostrom , Michael J. Rice , Raymond D. Skwierczynski
发明人： David Ach , Hughes Martin , Anna Van , Joel R. Jacobson , Junshi Y. Wu , Kyle J. Lindstrom , Tai T. Tran , Myles L. Brostrom , Michael J. Rice , Raymond D. Skwierczynski
IPC分类号： A61K31/4375 , C07D471/14 , A61P35/00
CPC分类号： C07D471/14
摘要： The invention provides various crystalline forms of 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate, pharmaceutical compositions, methods of making, and methods of use.
摘要翻译： 本发明提供各种结晶形式的1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1,5]萘啶-4-胺乙磺酸盐，药物组合物，制备方法和使用方法。
-
3.发明申请PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER AND OTHER DISEASES OR DISORDERS 审中-公开用于治疗癌症及其他疾病或病症的药物组合物公开(公告)号：US20110039826A1
公开(公告)日：2011-02-17
申请号：US12844920
申请日：2010-07-28
CPC分类号： A61K31/55 , A61K9/08 , A61K47/02 , A61K47/10 , A61K47/14 , A61K47/20 , A61K47/26 , C07D487/04
摘要： This invention provides novel pharmaceutical compositions of the compound of formula (I): or a pharmaceutically acceptable salt thereof, that are suitable for the bulk production of an oral pharmaceutical dosage form; processes for the production of said oral pharmaceutical dosage form; and the use of the pharmaceutical composition for the treatment of patients suffering from or subject to diseases, disorders, or conditions involving cell survival, proliferation and migration, including chronic inflammatory proliferative disorders, proliferative ocular disorders, benign proliferative disorders, and cancer.
摘要翻译： 本发明提供了适用于大量生产口服药物剂型的式（I）化合物或其药学上可接受的盐的新型药物组合物： 用于生产所述口服药物剂型的方法; 以及该药物组合物用于治疗患有或患有涉及细胞存活，增殖和迁移的疾病，病症或病症的患者的用途，包括慢性炎性增生性疾病，增殖性眼部疾病，良性增殖性疾病和癌症。
-
公开(公告)号：US20090325903A1
公开(公告)日：2009-12-31
申请号：US12485344
申请日：2009-06-16
申请人： Eric L. Elliott , Abu J. Ferdous , Michael J. Kaufman , Sonja A. Komar , Debra L. Mazaik , Quentin J. McCubbin , Phuong Nguyen , Vaithianathan Palaniappan , Raymond D. Skwierczynski , Nobel T. Truong , Csanad M. Varga , Peter N. Zawaneh
发明人： Eric L. Elliott , Abu J. Ferdous , Michael J. Kaufman , Sonja A. Komar , Debra L. Mazaik , Quentin J. McCubbin , Phuong Nguyen , Vaithianathan Palaniappan , Raymond D. Skwierczynski , Nobel T. Truong , Csanad M. Varga , Peter N. Zawaneh
CPC分类号： C07F5/04 , A61K31/198 , A61K31/454 , A61K31/69 , C07C233/83 , C07F5/025 , C07K5/06139 , C07K5/06191
摘要： The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
摘要翻译： 本发明提供了可用作蛋白酶体抑制剂的新化合物。 本发明还提供包含本发明化合物的药物组合物和使用该组合物治疗各种疾病的方法。
-
![Aqueous Gel Formulations Containing 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine](/abs-image/US/2008/08/28/US20080207675A1/abs.jpg.150x150.jpg)
5.发明申请Aqueous Gel Formulations Containing 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine 审中-公开含有1-（2-甲基丙基）-1H-咪唑并[4,5-C] [1,5]萘啶-4-胺的水凝胶制剂公开(公告)号：US20080207675A1
公开(公告)日：2008-08-28
申请号：US11815491
申请日：2006-02-03
IPC分类号： A61K31/437 , C07D471/12 , A61P1/04
CPC分类号： A61K31/4745 , A61K9/06 , A61K31/437 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/36
摘要： Pharmaceutical formulations in an aqueous gel formulation including 1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine are provided. Methods of use and kits are also provided.
摘要翻译： 提供包含1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1,5]萘啶-4-胺的水性凝胶制剂中的药物制剂。 还提供使用方法和试剂盒。
-
6.发明授权Formulations and methods for treatment of mucosal associated conditions with an immune response modifier 有权用免疫反应调节剂治疗粘膜相关病症的制剂和方法公开(公告)号：US06245776B1
公开(公告)日：2001-06-12
申请号：US09479578
申请日：2000-01-07
申请人： Raymond D. Skwierczynski , Kenneth R. Phares , Richard L. Miller , Zheng Jane Li , Michael J. Jozwiakowski , Terri F. Busch
发明人： Raymond D. Skwierczynski , Kenneth R. Phares , Richard L. Miller , Zheng Jane Li , Michael J. Jozwiakowski , Terri F. Busch
IPC分类号： A61K3144
CPC分类号： A61K9/0034 , A61K9/0014 , A61K31/437 , A61K31/44 , A61K31/4745 , A61K47/10 , A61K47/12 , C07D471/04
摘要： Immune response modifier (IRM) compounds—imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo- and oxazolo-quinolinamines and pyridinamines, imidazonaphthyridine and tetrahydroimidazonaphthyridine amines—are useful for the treatment of conditions at and below the mucosal surfaces by administering a therapeutically effective amount of such compounds to the mucosal surface. Novel pharmaceutical formulations are provided. In one embodiment, the pharmaceutical formulations are advantageous for treatment of cervical conditions such as cervical dysplasias including cervical intraepithelial neoplasias.
摘要翻译： 免疫应答调节剂（IRM）化合物 - 咪唑并喹啉胺，咪唑并吡啶胺，6,7-稠合环烷基咪唑并吡啶胺，1,2-桥连咪唑并喹啉胺，噻唑并恶唑并喹啉胺和吡啶胺，咪唑并吡啶和四氢咪唑并吡啶胺 - 可用于治疗 通过向粘膜表面施用治疗有效量的这种化合物，在粘膜表面和下方的条件。 提供了新的药物制剂。 在一个实施方案中，药物制剂对于治疗子宫颈病症例如宫颈发育不良（包括宫颈上皮内瘤变）是有利的。
-
公开(公告)号：US09248127B2
公开(公告)日：2016-02-02
申请号：US11883665
申请日：2006-02-03
IPC分类号： A01N43/42 , A61K31/44 , A01N43/50 , A61K31/415 , A61K31/4745 , A61K9/00 , A61K47/10 , A61K47/12 , A61K47/32 , A61K47/36
CPC分类号： A61K39/39 , A61K9/0034 , A61K9/06 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/32 , A61K47/36 , A61M31/007
摘要： Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided.
摘要翻译： 包括免疫应答调节剂（IRM）的水性凝胶制剂，例如选自咪唑并喹啉胺，四氢咪唑并喹啉胺，咪唑并吡啶胺，6,7-稠合的环烷基咪唑并吡啶胺，1,2-桥连的咪唑并喹啉胺，咪唑并吡啶胺，咪唑并四氢萘并吡啶胺，恶唑并喹啉 胺，噻唑并喹啉胺，恶唑啉吡啶胺，噻唑并吡啶胺，恶唑烷基吡啶胺，噻唑烷萘啶胺，吡唑并吡啶胺，吡唑并喹啉胺，四氢吡唑并喹啉胺，吡唑并萘啶胺，四氢吡唑并萘啶胺和与吡啶胺，喹啉胺，四氢喹啉胺，萘啶胺相融合的1H-咪唑二聚体 ，或四氢萘啶胺。 还提供使用方法和试剂盒。
-
公开(公告)号：US07968562B2
公开(公告)日：2011-06-28
申请号：US12172712
申请日：2008-07-14
申请人： Raymond D. Skwierczynski , Terri F. Busch , Amy L. Gust-Heiting , Mary Fretland , Matthew T. Scholz
发明人： Raymond D. Skwierczynski , Terri F. Busch , Amy L. Gust-Heiting , Mary Fretland , Matthew T. Scholz
IPC分类号： A01N43/42 , A01N43/50 , A61K31/44 , A61K31/415 , C07D471/00 , C07D491/00 , C07D498/00 , C07D513/00 , C07D515/00
CPC分类号： A61K31/437 , A61K9/0014 , A61K31/4355 , A61K31/4365 , A61K31/4375 , A61K31/4745 , A61K47/10 , A61K47/14 , A61K47/32 , A61K47/36 , A61K47/44
摘要： Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.
摘要翻译： 包含选自咪唑并喹啉胺，咪唑四氢喹啉胺，咪唑并吡啶胺，6,7-稠合的环烷基咪唑并吡啶胺，1,2-桥连的咪唑并喹啉胺，噻唑并喹啉胺，恶唑并喹啉胺，噻唑并 - 吡啶胺，恶唑啉 吡啶胺，咪唑并吡啶胺，四氢咪唑并吡啶胺和噻唑烷吡啶胺; 脂肪酸 并且与脂肪酸可混溶的疏水性非质子组分可用于治疗真皮相关病症。 提供新的局部制剂。 在一个实施方案中，局部制剂有利于治疗光化性角化病，术后瘢痕，基底细胞癌，特应性皮炎和疣。
-
公开(公告)号：US20090163532A1
公开(公告)日：2009-06-25
申请号：US11883665
申请日：2006-02-03
IPC分类号： A61K31/437 , A61K31/4738 , A61P31/00
CPC分类号： A61K39/39 , A61K9/0034 , A61K9/06 , A61K31/4745 , A61K47/10 , A61K47/12 , A61K47/20 , A61K47/32 , A61K47/36 , A61M31/007
摘要： Aqueous gel formulations, including an immune response modifier (IRM), such as those chosen from imidazoquinoline amines, tetrahydroimidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, imidazonaphthyridine amines, imidazotetrahydronaphthyridine amines, oxazoloquinoline amines, thiazoloquinoline amines, oxazolopyridine amines, thiazolopyridine amines, oxazolonaphthyridine amines, thiazolonaphthyridine amines, pyrazolopyridine amines, pyrazoloquinoline amines, tetrahydropyrazoloquinoline amines, pyrazolonaphthyridine amines, tetrahydropyrazolonaphthyridine amines, and 1H-imidazo dimers fused to pyridine amines, quinoline amines, tetrahydroquinoline amines, naphthyridine amines, or tetrahydronaphthyridine amines, are provided. Methods of use and kits are also provided.
摘要翻译： 包括免疫应答调节剂（IRM）的水性凝胶制剂，例如选自咪唑并喹啉胺，四氢咪唑并喹啉胺，咪唑并吡啶胺，6,7-稠合的环烷基咪唑并吡啶胺，1,2-桥连的咪唑并喹啉胺，咪唑并吡啶胺，咪唑并四氢萘并吡啶胺，恶唑并喹啉 胺，噻唑并喹啉胺，恶唑啉吡啶胺，噻唑并吡啶胺，恶唑烷基吡啶胺，噻唑烷萘啶胺，吡唑并吡啶胺，吡唑并喹啉胺，四氢吡唑并喹啉胺，吡唑并萘啶胺，四氢吡唑并萘啶胺和与吡啶胺，喹啉胺，四氢喹啉胺，萘啶胺相融合的1H-咪唑二聚体 ，或四氢萘啶胺。 还提供使用方法和试剂盒。
-
公开(公告)号：US20080275077A1
公开(公告)日：2008-11-06
申请号：US12172712
申请日：2008-07-14
申请人： Raymond D. Skwierczynski , Terri F. Busch , Amy L. Gust-Heiting , Mary Fretland , Matthew T. Scholz
发明人： Raymond D. Skwierczynski , Terri F. Busch , Amy L. Gust-Heiting , Mary Fretland , Matthew T. Scholz
IPC分类号： A61K31/437 , A61P17/00 , A61P35/00
CPC分类号： A61K31/437 , A61K9/0014 , A61K31/4355 , A61K31/4365 , A61K31/4375 , A61K31/4745 , A61K47/10 , A61K47/14 , A61K47/32 , A61K47/36 , A61K47/44
摘要： Pharmaceutical formulations comprising an immune response modifier (IRM) chosen from imidazoquinoline amines, imidazotetrahydroquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, 1,2-bridged imidazoquinoline amines, thiazolo-quinolineamines, oxazolo-quinolinamines, thiazolo-pyridinamines, oxazolo-pyridinamines, imidazonaphthyridine amines, tetrahydroimidazonaphthyridine amines, and thiazolonaphthyridine amines; a fatty acid; and a hydrophobic, aprotic component miscible with the fatty acid are useful for the treatment of dermal associated conditions. Novel topical formulations are provided. In one embodiment, the topical formulations are advantageous for treatment of actinic keratosis, postsurgical scars, basal cell carcinoma, atopic dermatitis, and warts.
摘要翻译： 包含选自咪唑并喹啉胺，咪唑四氢喹啉胺，咪唑并吡啶胺，6,7-稠合的环烷基咪唑并吡啶胺，1,2-桥连的咪唑并喹啉胺，噻唑并喹啉胺，恶唑并喹啉胺，噻唑并 - 吡啶胺，恶唑啉 吡啶胺，咪唑并吡啶胺，四氢咪唑并吡啶胺和噻唑烷吡啶胺; 脂肪酸 并且与脂肪酸可混溶的疏水性非质子组分可用于治疗真皮相关病症。 提供新的局部制剂。 在一个实施方案中，局部制剂有利于治疗光化性角化病，术后瘢痕，基底细胞癌，特应性皮炎和疣。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.036 秒)
